These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 12911535)
1. Combining lisinopril and l-arginine slows disease progression and reduces endothelin-1 in passive Heymann nephritis. Zoja C; Benigni A; Camozzi D; Corna D; Longaretti L; Todeschini M; Remuzzi G Kidney Int; 2003 Sep; 64(3):857-63. PubMed ID: 12911535 [TBL] [Abstract][Full Text] [Related]
2. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Zoja C; Corna D; Rottoli D; Cattaneo D; Zanchi C; Tomasoni S; Abbate M; Remuzzi G Kidney Int; 2002 May; 61(5):1635-45. PubMed ID: 11967013 [TBL] [Abstract][Full Text] [Related]
3. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. Zoja C; Corna D; Camozzi D; Cattaneo D; Rottoli D; Batani C; Zanchi C; Abbate M; Remuzzi G J Am Soc Nephrol; 2002 Dec; 13(12):2898-908. PubMed ID: 12444208 [TBL] [Abstract][Full Text] [Related]
4. The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist. Zoja C; Donadelli R; Corna D; Testa D; Facchinetti D; Maffi R; Luzzana E; Colosio V; Bertani T; Remuzzi G Am J Kidney Dis; 1997 Feb; 29(2):254-64. PubMed ID: 9016898 [TBL] [Abstract][Full Text] [Related]
5. Angiotensin II blockade limits tubular protein overreabsorption and the consequent upregulation of endothelin 1 gene in experimental membranous nephropathy. Zoja C; Liu XH; Abbate M; Corna D; Schiffrin EL; Remuzzi G; Benigni A Exp Nephrol; 1998; 6(2):121-31. PubMed ID: 9567218 [TBL] [Abstract][Full Text] [Related]
7. Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. Benigni A; Zoja C; Zatelli C; Corna D; Longaretti L; Rottoli D; Maggioni P; Todeschini M; Noris M; Remuzzi G Kidney Int; 2004 Nov; 66(5):1959-65. PubMed ID: 15496167 [TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibition prevents glomerular-tubule disconnection and atrophy in passive Heymann nephritis, an effect not observed with a calcium antagonist. Benigni A; Gagliardini E; Remuzzi A; Corna D; Remuzzi G Am J Pathol; 2001 Nov; 159(5):1743-50. PubMed ID: 11696435 [TBL] [Abstract][Full Text] [Related]
9. Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. Benigni A; Corna D; Maffi R; Benedetti G; Zoja C; Remuzzi G Kidney Int; 1998 Aug; 54(2):353-9. PubMed ID: 9690201 [TBL] [Abstract][Full Text] [Related]
10. Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis. Zoja C; Abbate M; Corna D; Capitanio M; Donadelli R; Bruzzi I; Oldroyd S; Benigni A; Remuzzi G Am J Kidney Dis; 1998 Mar; 31(3):453-63. PubMed ID: 9506682 [TBL] [Abstract][Full Text] [Related]
11. ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy. Remuzzi A; Fassi A; Bertani T; Perico N; Remuzzi G Am J Kidney Dis; 1999 Oct; 34(4):626-32. PubMed ID: 10516341 [TBL] [Abstract][Full Text] [Related]
12. Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. Benigni A; Zoja C; Noris M; Corna D; Benedetti G; Bruzzi I; Todeschini M; Remuzzi G Am J Kidney Dis; 1999 Apr; 33(4):746-53. PubMed ID: 10196019 [TBL] [Abstract][Full Text] [Related]
13. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. Zoja C; Corna D; Gagliardini E; Conti S; Arnaboldi L; Benigni A; Remuzzi G Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975 [TBL] [Abstract][Full Text] [Related]
15. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. Gagliardini E; Corna D; Zoja C; Sangalli F; Carrara F; Rossi M; Conti S; Rottoli D; Longaretti L; Remuzzi A; Remuzzi G; Benigni A Am J Physiol Renal Physiol; 2009 Nov; 297(5):F1448-56. PubMed ID: 19675181 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic resistance to angiotensin converting enzyme (ACE) inhibition is related to pharmacodynamic and -kinetic factors in 5/6 nephrectomized rats. Windt WA; van Dokkum RP; Kluppel CA; Jeronimus-Stratingh CM; Hut F; de Zeeuw D; Henning RH Eur J Pharmacol; 2008 Feb; 580(1-2):231-40. PubMed ID: 18036585 [TBL] [Abstract][Full Text] [Related]
17. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. Benigni A; Zoja C; Corna D; Zatelli C; Conti S; Campana M; Gagliardini E; Rottoli D; Zanchi C; Abbate M; Ledbetter S; Remuzzi G J Am Soc Nephrol; 2003 Jul; 14(7):1816-24. PubMed ID: 12819241 [TBL] [Abstract][Full Text] [Related]
18. Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Remuzzi A; Gagliardini E; Donadoni C; Fassi A; Sangalli F; Lepre MS; Remuzzi G; Benigni A Kidney Int; 2002 Sep; 62(3):885-94. PubMed ID: 12164870 [TBL] [Abstract][Full Text] [Related]
19. Addition of AT1 blocker fails to overcome resistance to ACE inhibition in adriamycin nephrosis. Bos H; Henning RH; De Boer E; Tiebosch AT; De Jong PE; De Zeeuw D; Navis G Kidney Int; 2002 Feb; 61(2):473-80. PubMed ID: 11849387 [TBL] [Abstract][Full Text] [Related]
20. Angiotensin-converting enzyme inhibition prevents loss of glomerular hydraulic permeability in passive heymann nephritis. Remuzzi A; Monaci N; Bonassi ME; Corna D; Zoja C; Mohammed EI; Remuzzi G Lab Invest; 1999 Dec; 79(12):1501-10. PubMed ID: 10616201 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]